Membership Update – October 2011

BioNJ welcomes GCA Therapeutics, Ltd., and iBio, Inc., as new Core Members for 2011:

GCA Therapeutics, Ltd.
GCA Therapeutics, Ltd. (GCAT) is a US-based, specialty pharmaceutical company focusing on in-licensing, acquisition, and marketing of mid- through late-stage drug candidates and technologies from North America and the EU. GCAT applies its expertise and resources in pre-clinical, clinical, and final regulatory review and approval phases to commercialize products for use in the Chinese market. GCAT is currently in discussion with several US and European biotech and pharma firms to bring several important drugs to market through its joint venture in Tianjin, China. Initially, GCAT will market its products through a third-party distribution/sales partnership and will construct or acquire manufacture capabilities in China at a later date. GCAT currently has operations in New Jersey, New York, Shanghai, and Beijing.

iBio, Inc.
iBio, Inc. (IBIO:AMEX), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBioLaunch™ platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins, and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems. Our technology has been validated across a wide range of applications in both vaccines and biotherapeutics, and these products are available for license along with the technology to bring innovative medicines to patients.

BioNJ welcomes ACT Oncology, LLC, and Alchimia Partners, LLC, as new Associate Members for 2011:

ACT Oncology, LLC
ACT Oncology, LLC, is a specialized oncology CRO comprising highly experienced clinical research professionals. Founded by Patricia Devitt Risse, PharmD, in 2000, and certified as a Woman-owned Business Enterprise by the State of New Jersey, the company has expanded from a core group focused on specific high-level oncology operations to a robust organization providing broad, full-service support for Phase I-III oncology programs and registries. Over the last decade, our clients have diversified to include leading biotech, pharma, and non-profit oncology organizations.

We place great emphasis on ensuring clear communication and on developing creative solutions to operational challenges. And because of our flat organizational structure, which focuses on supporting our project teams, sponsors receive flexible, responsive and cost-effective services.

Repeat business from our sponsors and increased demand for our oncology services has enabled ACT Oncology to steadily expand our geographic presence in North America and to include project management and monitoring services in the UK. Our key sponsors regularly offer to provide references on our behalf to prospective clients.

Alchimia Partners, LLC
Alchimia Partners, LLC, offers consulting services to biotechnology and pharmaceutical companies, to investors in those companies, and to other organizations requiring insight or expertise related to the biopharmaceutical industry. Our principle, Tony Fiorino, MD, PhD, brings a unique background and skill set to this consulting practice. Tony founded, and served as President and CEO, of EnzymeRx, LLC, where he led the clinical development of pegylated uricase through Phase I and successfully executed the sale of the program. Before founding EnzymeRx, Tony spent 10 years on Wall Street as a biotechnology and pharmaceutical analyst and portfolio manager. Tony trained in medicine and dermatology at the Hospital of the University of Pennsylvania after completing the MD-PhD program at the Albert Einstein College of Medicine, and received a BS in Biology from MIT. With the experiences and skills built across his career, Tony is equally conversant in basic science, clinical medicine, drug development, financial modeling, and healthcare investing, and he applies this unique, multi-disciplined and strategic vision to each engagement.

BioNJ Thanks Core Members Helsinn Therapeutics, USA and Unigene Laboratories, Inc. for Renewing Their Membership for 2011

Helsinn Therapeutics, USA
Helsinn Therapeutics USA is a privately held biopharmaceutical development company whose management has leadership experience with major pharmaceutical companies such as Roche, Merck, Aventis, and Novartis. The team’s experience ranges through all aspects of drug development — from research, safety assessment and manufacturing through regulatory affairs and commercialization. Our pipeline consists of first-in-class, composition-of-matter protected compounds acting within the ghrelin pathway.

Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a biopharmaceutical company engaged in the research, production, and delivery of valuable therapeutic peptide hormones for pharmaceutical purposes.